

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/644,027	08/19/2003	George N. Pavlakis	015280-257300US 5339		
20350 7590 09/11/2007 TOWNSEND AND TOWNSEND AND CREW, LLP TWO EMBARCADERO CENTER;			EXAMINER		
			PARKIN, JEFFREY S		
EIGHTH FLOO	OR SCO, CA 94111-3834	ART UNIT	PAPER NUMBER		
	000, 0113 1111 203 1		. 1648		
			MAIL DATE	DELIVERY MODE	
			09/11/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.



Director of the United States Patent and Trademark Office P.O. Box 1450

Alexandria, Virginia 22313-1450

DEA/FCE-1994

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
10/644,027	08/19/2003	Pavlakis, G. N.	015280-257300US

EXAMINER				
Jeffrey S. Parkin, Ph.D).			
ART UNIT	PAPER NUMBER			
1648	09/03/2007			

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application Commissioner of Patents

Acknowledgement is hereby made of receipt and entry of the communication filed 01 June, 2007. However, as previously set forth, this application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2) (e.g., see Figures 2-4, 12, and 17). However, this application fails to comply with the requirements of 37 C.F.R. § 1.821 through 1.825 for the reason(s) set forth below or on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicants are reminded that sequences appearing in the specification and/or drawings must be identified by a sequence identifier (SEO ID NO.:) in accordance with 37 C.F.R. § 1.821(d). Applicant must provide appropriate amendments to the specification inserting the required drawings sequence identifiers. Extensive amendments may necessitate the submission of a substitute specification.

APPLICANT IS GIVEN ONE MONTH, OR THIRTY DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R. §s 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the

Notice to Comply

Application No.	Applicant(s)	
10/644,027	Pavlakis, G. N.	
Examiner	Art Unit	Paper No.
Jeffrey S. Parkin	1648	09/03/2007

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

requirements for such a disclosure as set forth in 37 C.F.N. 1.021 - 1.025 for the following reason(s).
1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other: Applicants are reminded that sequences appearing in the specification and/or drawings must be identified by a sequence identifier (SEQ ID NO.:) in accordance with 37 C.F.R. 1.821(d). Sequence identifiers for sequences appearing in the drawings may appear in the Brief Description of the Drawings. Applicant must provide appropriate amendments to the specification and/or drawings inserting the required sequence identifiers. Extensive amendments may necessitate the submission of a substitute specification and drawings.
Applicant May Need to Provide: ☑ An substitute computer readable form (CRF) copy of the "Sequence Listing".
An substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov.

To Download Patentin Software, visit http://www.uspto.gov/web/patents/software.htm.

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

Serial No.: 10/644,027 Applicant: Pavlakis, G. N.

attached Notice to Comply with the response.

Correspondence

Any inquiry concerning this communication should be directed to Jeffrey S. Parkin, Ph.D., whose telephone number is (571) 272-0908. The examiner can normally be reached Monday through Thursday from 10:30 AM to 9:00 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Bruce R. Campell, Ph.D., can be reached at (571) 272-0974. Direct general status inquiries to the Technology Center 1600 receptionist at (571) 272-1600. Informal communications may be submitted to the Examiner's RightFAX account at (571) 273-0908.

Applicants are reminded that the United States Patent and Trademark Office (Office) requires most patent related correspondence to be: a) faxed to the Central FAX number (571-273-8300) (updated as of July 15, 2005), b) hand carried or delivered to the Customer Service Window (now located at the Randolph Building, 401 Dulany Street, Alexandria, VA 22314), c) mailed to the mailing address set forth in 37 C.F.R. § (e.g., P.O. Box 1450, Alexandria, VA 22313-1450), transmitted to the Office using the Office's Electronic Filing System. This notice replaces all prior Office notices specifying a specific hand carry address for certain patent related fax number or For further information refer to the Updated Notice correspondence. of Centralized Delivery and Facsimile Transmission Policy for Patent Related Correspondence, and Exceptions Thereto, 1292 Off. Gaz. Pat. Office 186 (March 29, 2005).

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Please direct all replies to the United States Patent and Trademark Office via one of the following: 1) Electronically submitted through EFS-Bio (http://www.uspto.gov/ebc/efs/downloads/documents.htm, EFS Submission User Manual - ePAVE); 2) Mailed to: Mail Stop Sequence, Commissioner for Patents, P.O. Box 22313-1450, Alexandria, VA 22313-1450; and 3) Hand Carry, Federal Express, United Parcel Service or other delivery service to: U.S. Patent and Trademark Office, Mail Stop Sequence, Customer Window, Randolph Building, 401 Dulaney Street, Alexandria, VA 22314.

Serial No.: 10/644,027 Applicant: Pavlakis, G. N.

Respectfully,

Jeffrey S. Parkin, Ph.D. Primary Examiner
Art Unit 1648

03 September, 2007